a short essay summarizing their achievements in cancer research. As illustrated in their essays, these outstanding young scholars have received excellent training under their US mentors who are USCACA members. These talented young scientists have not only made impressive discoveries in the mechanisms underlying the causes or progression of human cancers, but also discovered new approaches for improving treatments for cancer patients. Our ultimate goal is to expedite novel cancer drug development by stimulating the translation of laboratory findings into novel cancer therapies, fostering collaborations in clinical cancer drug development, and sharing expert knowledge and medical practices between China and the United States. In Dr. Zhang's laboratory, Dr. Sun investigated a master microRNA-mRNA network that regulates epithelial-tomesenchymal transition (EMT) in malignant ovarian cancer. Dr. Sun and her colleagues demonstrated that miR-506 acts as a key node in this novel miRNA-mRNA network promoting EMT in ovarian cancer. This outstanding study was published in Cancer Cell and featured on the cover of the same issue of the journal. In a personalized medicine project on ovarian cancer in collaboration with The Cancer Genome Atlas project, Dr. Sun performed integrated analyses on the multidimensional genomic, epigenetic, and clinical data of 316 high-grade serous ovarian cancer cases. These analyses led to the discovery that BRCA2 mutations are associated with improved survival and improved chemotherapy response compared with BRCA wildtype or BRCA1 mutations. The study was published in JAMA and highlighted in an editorial comment of Nature Reviews Cancer and other highimpact journals. In another study on colorectal cancer, Dr. Sun showed that NGAL expression was elevated during the normal mucosa-adenomaadenocarcinoma sequence, and high NGAL expression promoted tumor growth and liver metastasis in mouse models and was associated with poor survival for patients. 
